The Role of Pathology Correlation Approach in Prostate Cancer Index Lesion Detection and Quantitative Analysis with Multiparametric MRI

Rationale and Objectives Development of imaging biomarkers often relies on their correlation with histopathology. Our aim was to compare two approaches for correlating pathology to multiparametric magnetic resonance (MR) imaging (mpMRI) for localization and quantitative assessment of prostate cancer (PCa) index tumor using whole mount (WM) pathology (WMP) as the reference. Materials and Methods Patients (N = 30) underwent mpMRI that included diffusion-weighted imaging and dynamic contrast-enhanced (DCE) MRI at 3 T before radical prostatectomy (RP). RP specimens were processed using WM technique (WMP) and findings summarized in a standard surgical pathology report (SPR). Histology index tumor volumes (HTVs) were compared to MR tumor volumes (MRTVs) using two approaches for index lesion identification on mpMRI using annotated WMP slides as the reference (WMP) and using routine SPR as the reference. Consistency of index tumor localization, tumor volume, and mean values of the derived quantitative parameters (mean apparent diffusion coefficient [ADC], Ktrans, and ve) were compared. Results Index lesions from 16 of 30 patients met the selection criteria. There was WMP/SRP agreement in index tumor in 13 of 16 patients. ADC-based MRTVs were larger (P < .05) than DCE-based MRTVs. ADC MRTVs were smaller than HTV (P < .005). There was a strong correlation between HTV and MRTV (Pearson r > 0.8; P < .05). No significant differences were observed in the mean values of Ktrans and ADC between the WMP and SPR. Conclusions WMP correlation is superior to SPR for accurate localization of all index lesions. The use of WMP is however not required to distinguish significant differences of mean values of quantitative MRI parameters within tumor volume.

[1]  A. Svindland,et al.  1061 Detection of the index tumor and tumor volume in prostate cancer using T2w and DW MRI alone , 2014 .

[2]  Jan van der Meulen,et al.  Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. , 2013, Radiology.

[3]  Andriy Fedorov,et al.  Practical considerations in T1 mapping of prostate for dynamic contrast enhancement pharmacokinetic analyses. , 2012, Magnetic resonance imaging.

[4]  Evis Sala,et al.  Dynamic contrast‐enhanced MRI in ovarian cancer: Initial experience at 3 tesla in primary and metastatic disease , 2010, Magnetic resonance in medicine.

[5]  Bin Wang,et al.  Diffusion‐weighted imaging of prostate cancer: Correlation between apparent diffusion coefficient values and tumor proliferation , 2009, Journal of magnetic resonance imaging : JMRI.

[6]  A. Evans,et al.  Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. , 2010, Radiology.

[7]  E. Rostrup,et al.  Measurement of the arterial concentration of Gd‐DTPA using MRI: A step toward quantitative perfusion imaging , 1996, Magnetic resonance in medicine.

[8]  J. A. Campbell,et al.  ACADEMIC RADIOLOGY. , 1965, The American journal of roentgenology, radium therapy, and nuclear medicine.

[9]  H. Hricak,et al.  Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. , 2008, Radiology.

[10]  Henry Rusinek,et al.  Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co‐registration software , 2014, BJU international.

[11]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[12]  A S Whittemore,et al.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.

[13]  L. Turnbull,et al.  Description of magnetic resonance imaging‐derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions , 2009, BJU international.

[14]  Jason A Koutcher,et al.  Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. , 2009, Radiology.

[15]  P. Choyke,et al.  Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer , 2013, Cancer.

[16]  H. Weinmann,et al.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.

[17]  M Bolla,et al.  EAU guidelines on prostate cancer . Part I : screening , diagnosis , and treatment of clinically localised disease , 2012 .

[18]  Theodorus H van der Kwast,et al.  A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. , 2011, The Journal of urology.

[19]  N. Rofsky,et al.  MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. , 2004, Radiology.

[20]  M. Rubin,et al.  Whole mounted radical prostatectomy specimens do not increase detection of adverse pathological features. , 2000, The Journal of urology.

[21]  T. Stamey,et al.  Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. , 2002, Urology.

[22]  A. Svindland,et al.  Detection of the index tumour and tumour volume in prostate cancer using T2‐weighted and diffusion‐weighted magnetic resonance imaging (MRI) alone , 2014, BJU international.

[23]  Silvia D. Chang,et al.  Combined diffusion‐weighted and dynamic contrast‐enhanced MRI for prostate cancer diagnosis—Correlation with biopsy and histopathology , 2006, Journal of magnetic resonance imaging : JMRI.

[24]  V. Reuter,et al.  Clinical significance of repeat sextant biopsies in prostate cancer patients. , 1997, Urology.

[25]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[26]  Magnus Hellström,et al.  Tissue shrinkage after fixation with formalin injection of prostatectomy specimens , 2006, Virchows Archiv.

[27]  B. Carey,et al.  Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. , 2011, European urology.

[28]  T. Stamey,et al.  Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. , 2003, The Journal of urology.

[29]  Milan Sonka,et al.  3D Slicer as an image computing platform for the Quantitative Imaging Network. , 2012, Magnetic resonance imaging.

[30]  Ron Kikinis,et al.  Statistical validation of image segmentation quality based on a spatial overlap index. , 2004, Academic radiology.

[31]  Baris Turkbey,et al.  Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. , 2011, The Journal of urology.

[32]  Aaron Fenster,et al.  Prostate: registration of digital histopathologic images to in vivo MR images acquired by using endorectal receive coil. , 2012, Radiology.

[33]  Lara Dyke Magnetic Resonance Angiography: Principles and Applications. , 2013, Medical physics.

[34]  Y. Liu,et al.  Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. , 2008, Clinical radiology.

[35]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[36]  Theodore L. DeWeese,et al.  Localized Prostate Cancer , 2007 .

[37]  F. Beuvon,et al.  Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation? , 2014, The Journal of urology.

[38]  Bing Ma,et al.  Challenges in accurate registration of 3-D medical imaging and histopathology in primary prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  Baris Turkbey,et al.  Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer. , 2012, Urology.

[40]  P. Walsh,et al.  Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. , 1997, The Journal of urology.

[41]  Stephan E Maier,et al.  Multiparametric MRI of prostate cancer: An update on state‐of‐the‐art techniques and their performance in detecting and localizing prostate cancer , 2013, Journal of magnetic resonance imaging : JMRI.

[42]  Baris Turkbey,et al.  Correlation of magnetic resonance imaging tumor volume with histopathology. , 2012, The Journal of urology.

[43]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[44]  I. Thompson,et al.  Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. , 1998, The Journal of urology.